MYL12B

Across TCGA pan-cancer cohorts, MYL12B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYL12B data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MYL12B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYL12B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where MYL12B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.466	0.876	.009	9	view →
CCRCC	DFS	Tertile	III,IV	0.905	0.514	.024	2	view →
LSCC	OS	Tertile	II,III,IV	0.767	0.430	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYL12B–LUAD (DFS)

Open the LUAD breakdown →